Two long-acting drugs from Immunwork will enter Phase I clinical trials this year !

The founder of Immunwork and T-E Meds, Dr. Tse-Wen Chang, shared the latest developments of the two companies on 11th January. He further announced Immunwork's planned entry into the clinical stage in 2024. The two long-acting drugs, TE-8105 and TE-8214, are designed to target type-II diabetes, obesity, fatty liver diseases, and neuroendocrine tumors (NETs) as well as acromegaly, respectively. Both drugs are scheduled to initiate Phase I clinical trials in Australia during the second quarter of 2024.